Neuroprotective properties of tianeptine: Interactions with cytokines

Neuropharmacology

Volumn 44, Issue 6, 2003, Pages 801-809

  Plaisant, F ^d   Dommergues, M A ^d   Spedding, M ^a   Cecchelli, R ^b   Brillault, J ^b   Kato, G ^c   Munoz C ^a   Gressens, P ^d  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b UNIVERSITÉ D'ARTOIS   (France)

^c MDS Pharma Services   (Switzerland)

^d HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

AMPA; Antidepressant; Hypoxia; Interleukin 1 ; Neuroprotection; NMDA

Indexed keywords

ANTIDEPRESSANT AGENT; DIZOCILPINE; IBOTENIC ACID; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TIANEPTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN CORTEX; BRAIN HYPOXIA; BRAIN INJURY; BRAIN NERVE CELL; CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; ENANTIOMER; ENZYME RELEASE; NERVE CELL PLASTICITY; NEUROPROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; WHITE MATTER;

EID: 0037401597     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(03)00066-2     Document Type: Article

References (50)

1. Bubser M., Tzschentke T., Hauber W. Behavioral and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats. Journal of Neural Transmission General Section. 101:1995;115-126.
2. Cassano G.B., Heinze G., Lôo H., Mendlewicz J., Paes de Sousa M. A double-blind comparison of tianeptine, imipramine and placebo in the treatment of major depressive episodes. European Psychiatry. 11:1996;254-259.
3. Castanon N., Bluthé R.M., Dantzer R. Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1β in the rat. Psychopharmacology. 154:2001;50-60.
4. Castanon N., Konsman J.P., Médina C., Chauvet N., Dantzer R. Chronic treatment with the atypical antidepressant tianeptine attenuates lipopolysaccharide-induced Fos expression in the rat paraventricular nucleus and corticosterone secretion. Psychoneuroendocrinology. 28:2003;19-34.
5. Clark W.M. Cytokines and reperfusion injury. Neurology. 49:1997;S10-S14.
6. Connor T.J., Leonard B.E. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sciences. 62:1998;583-606.
7. Conrad C.D., Galea L.A.M., Kuroda Y., McEwen B.S. Chronic stress impairs rat spatial memory on the Y-maze and this effect is blocked by tianeptine pre-treatment. Behavioral Neuroscience. 110:1996;1321-1334.
8. Conrad C.D., Magariños A.M., Ledoux J.E., McEwen B.S. Repeated restraint stress facilitates fear conditioning independently of causing hippocampal CA3 dendritic atrophy. Behavioral Neuroscience. 113:1999;902-913.
9. Costa e Silva J.A., Ruschel S.I., Caetano D., Rocha F.L., da Silva Lippi J.R., Arruda S., et al. Placebo-controlled study of tianeptine in major depressive episodes. Neuropsychobiology. 35:1997;24-29.
10. Czeh B., Michaelis T., Watanabe T., Frahm J., de Biurrung G., Van Kampen M., et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proceedings of the National Academy of Sciences USA. 98:2001;12796-12801.
11. Dantzer R., Bluthé R.M., Gheusi G., Cremona S., Layé S., Parnet P., et al. Molecular basis of sickness behavior. Annals of Journal of New York Academy of Sciences USA. 856:1998;132-138.
12. Dantzer R., Wollman E., Vitkovic L., Yirmiya R. Cytokines and depression: fortuitous or causative association? Molecular Psychiatry. 4:1999;328-332.
13. Defrance R., Marey C., Kamoun A. Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials. Clinical Neuropharmacology. 11:1988;S74-S82.
14. De Lima A.D., Merten M.D., Voigt T. Neuritic differentiation and synaptogenesis in serum-free neuronal cultures of the rat cerebral cortex. Journal of Comparative Neurology. 382:1997;230-246.
15. Dommergues M.A., Patkai J., Renauld J.C., Evrard P., Gressens P. Pro-inflammatory cytokines and IL-9 exacerbate excitotoxic lesions of the newborn murine neopallium. Annals of Neurology. 47:2000;54-63.
16. Evrard P., Marret S., Gressens P. Environmental and genetic determinants of neural migration and postmigratory survival. Acta Paediatrica. 422:1997;20-26.
17. Garcia J.H., Liu K.F., Relton J.K. Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. American Journal of Pathology. 147:1995;1477-1486.
18. Gressens P., Marret S., Hill J.M., Brenneman D.E., Gozes I., Fridkin M., et al. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. Journal of Clinical Investment. 100:1997;390-397.
19. Gressens P., Besse L., Robberecht P., Gozes I., Fridkin M., Evrard P. Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives. Journal of Pharmacology and Experimental therapeutics. 288:1999;1207-1213.
20. Husson I., Mesplès B., Bac P., Vamecq J., Evrard P., Gressens P. Melatoninergic neuroprotection of the murine periventricular white matter against neonatal excitotoxic challenge. Annals of Neurology. 51:2002;82-92.
21. Kanemoto K., Kawasaki J., Miyamoto T., Obayashi H., Nishimura M. Interleukin (IL)-1b, IL-1a and IL-1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy. Annals of Neurology. 47:2000;571-574.
22. Kent S., Bluthé R.M., Kelley K.W., Dantzer R. Sickness behavior as a new target for drug development. Trends in Pharmacological Sciences. 13:1992;24-28.
23. Laudenbach V., Calo G., Guerrini R., Lamboley G., Benoist J.F., Evrard P., et al. Nocicieptin/orphanin FQ exacerbates excitotoxic white matter lesions in the murine neonatal brain. Journal of Clinical Investment. 107:2001;457-466.
24. Magariños A.M., McEwen B.S. Differential effects of chronic stress and oral corticosterone on the hippocampal mossy fiber terminals ultrastructure: prevention by tianeptine. Abstracts of Society of Neurosciences. 23:(720.4):1997;1849.
25. Magariños A.M., Deslandes A., McEwen B.S. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. European Journal of Pharmacology. 371:1999;113-122.
26. Marret S., Mukendi R., Gadisseux J.F., Gressens P., Evrard P. Effect of ibotenate on brain development: an excitotoxic mouse model of microgyria and posthypoxic-like lesions. Journal of Neuropathology and Experimental Neurology. 54:1995;358-370.
27. Marret S., Gressens P., Evrard P. Arrest of neuronal migration by excitatory amino acid in hamster developing brain. Proceedings of the National Academy of Sciences USA. 93:1996;15463-15468.
28. McEwen B.S. Possible mechanisms for atrophy of the human hippocampus. Molecular Psychiatry. 2:1997;255-262.
29. Morris R.G., Kelly S., Burney D., Anthony T., Deslandes A., Boyer P.A., et al. Tianeptine and its enantiomers: enhanced retention of spatial memory in animals with medial septum lesions. Neuropharmacology. 41:2001;272-281.
30. Nelson K.B., Dambrosia J.M., Grether J.K., Phillips T.M. Neonatal cytokines and coagulation factors in children with cerebral palsy. Annals of Neurology. 44:1998;665-675.
31. Pearson V.L., Rothwell N.J., Toulmond S. Excitotoxic brain damage in the rat induces interleukin-1β protein in microglia and astrocytes: correlation with the progression of cell death. Glia. 25:1999;311-323.
32. Qiu Z., Sweeney D.D., Netzeband J.G., Gruol D.L. Chronic interleukin-6 alters NMDA receptor-mediated membrane responses and enhances neurotoxicity in developing CNS neurons. Journal of Neuroscience. 18:1998;10445-10456.
33. Ramamoorthy S., Ramamoorthy J.D., Prasad P.D., Bhat G.K., Mahesh V.B., Leibach F.H., et al. Regulation of the human serotonin transporter by interleukin-1β Biochemical and Biophysical Research Communications. 216:1995;560-567.
34. Regan R.F., Choi D.W. The effect of NMDA, AMPA/kainate, and calcium channel antagonists on traumatic cortical neuronal injury in culture. Brain Research. 633:1994;236-242.
35. Relton J.K., Rothwell N.J. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Research Bulletin. 29:1992;243-246.
36. Relton J., Martin D., Thompson R., Russel D. Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Experimental Neurology. 138:1996;206-213.
37. Rothwell N.J. Cytokines and acute neurodegeneration. Molecular Psychiatry. 2:1997;120-121.
38. Saiz-Ruiz J., Montes J.M., Alvarez E., Cervera S., Giner J., Guerrero J., et al. Tianeptine therapy for depression in the elderly. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 22:1998;319-329.
39. Sattler R., Xiong Z., Lu W.Y., MacDonald J.F., Tymianski M. Distinct roles of synaptic and extrasynaptic NMDA receptors in excitotoxicity. Journal of Neuroscience. 20:2000;22-33.
40. Shakesby A.C., Anwyl R., Rowan M.J. Overcoming the effects of stress on synaptic plasticity in the intact hippocampus: rapid actions of serotonergic and antidepressant agents. Journal of Neuroscience. 22:2002;3638-3644.
41. Shintani F., Nakaki T., Kamba S., Kato R., Asai M. Role of interleukin-1 in stress responses. Molecular Neurobiology. 10:1995;47-71.
42. Tahraoui S.L., Marret S., Bodénant C., Leroux P., Dommergues M.A., Evrard P., et al. Central role of microglia in neonatal excitotoxic lesions of the murine periventricular white matter. Brain Pathology. 11:2001;56-71.
43. Takao T., Hashimoto K., De Souza E.B. Modulation of interleukin-1 receptors in the brain endocrine immune axis by stress and infection. Brain, Behavior, and Immunity. 9:1995;276-291.
44. Vizi E.S., Mike A., Tarnawa I. 2,3-benzodiazepines (GYKI 52466 and analogs): negative allosteric modulators of AMPA receptors. CNS Drug Review. 2:1996;91-126.
45. Watanabe Y., Gould E., Daniels D.C., Cameron H., McEwen B.S. Tianeptine attenuates stress-induced morphological changes in the hippocampus. European Journal of Pharmacology. 222:1992;157-162.
46. Wilde M.I., Benfield P. Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs. 49:1995;411-439.
47. Willins D.L., Narayanan S., Wallace L.J., Uretsky N.J. The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK801. Pharmacology, Biochemistry and Behavior. 45:1993;881-887.
48. Xia L., Matera C., Ferin M., Wardlaw S.L. Interleukin-1 stimulates the central release of corticotropin-releasing hormone in the primate. Neuroendocrinology. 63:1996;79-84.
49. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Research. 711:1996;163-174.
50. Zhang Z., Chopp M., Goussev A., Powers C. Cerebral vessels express interleukin 1β after focal cerebral ischemia. Brain Research. 784:1998;210-217.